Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals
- Author:
Dong Hoon LEE
1
;
Soo Hyung RYU
;
Hee jun MYUNG
;
Yun Jae SHIN
;
Si Hyeong LEE
;
Tae Young PARK
;
Jeong Seop MOON
Author Information
- Publication Type:CASE REPORT
- From:The Korean Journal of Gastroenterology 2021;77(2):88-91
- CountryRepublic of Korea
- Language:English
- Abstract: The pegylated interferon plus ribavirin combination therapy has been used as the primary treatment for chronic hepatitis C (CHC) but fails to produce a sustained viral response (SVR) in many patients. In recent years, the treatment of CHC has been rapidly changing because of the introduction of direct-acting antivirals (DAAs), which have a high cure rate. However, retreatment of patients after failure of the first DAA therapy is difficult. We report two rare cases of CHC that showed acquired SVR with other DAA combinations after failure to daclatasvir and asunaprevir.
